New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia
Press release – Oslo, Norway, September 20th, 2022: Photocure ASA, The Bladder Cancer Company, announces the publication of first results from the Laser III clinical study in the medical journal, European Urology. The study is part of a systematic program aimed at verifying the safe treatment of bladder tumors in the outpatient setting. Laser III results demonstrate the non-inferiority of outpatient laser-mediated destruction of bladder tumors in conjunction with blue light cystoscopy (BLC[®]) and Hexvix[®] versus inpatient BLC TURBT* under general anesthesia. Photocure has supported this